HC Wainwright Estimates Vericel’s Q4 Earnings (NASDAQ:VCEL)

Vericel Co. (NASDAQ:VCEL) – Equities research analysts at HC Wainwright decreased their Q4 2024 earnings estimates for Vericel in a research report issued on Friday, November 8th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings of $0.37 per share for the quarter, down from their prior forecast of $0.38. HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Vericel’s current full-year earnings is $0.13 per share. HC Wainwright also issued estimates for Vericel’s Q3 2025 earnings at $0.09 EPS.

Other research analysts have also issued research reports about the stock. Truist Financial increased their price target on shares of Vericel from $56.00 to $57.00 and gave the stock a “buy” rating in a research note on Tuesday, July 16th. Stephens increased their price target on shares of Vericel from $56.00 to $58.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Canaccord Genuity Group started coverage on shares of Vericel in a research note on Friday, August 9th. They set a “buy” rating and a $57.00 price target on the stock. StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research note on Friday, November 8th. Finally, TD Cowen upped their price objective on shares of Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, August 27th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $57.71.

Vericel Stock Down 1.6 %

Shares of VCEL opened at $55.89 on Monday. The company’s fifty day moving average is $44.37 and its 200-day moving average is $46.49. Vericel has a 12 month low of $32.31 and a 12 month high of $57.81. The firm has a market cap of $2.76 billion, a price-to-earnings ratio of 946.33 and a beta of 1.66.

Vericel (NASDAQ:VCEL) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. Vericel had a net margin of 1.56% and a return on equity of 1.48%. The business had revenue of $57.91 million for the quarter, compared to analyst estimates of $55.32 million.

Hedge Funds Weigh In On Vericel

A number of hedge funds have recently made changes to their positions in VCEL. Norden Group LLC acquired a new position in shares of Vericel in the 1st quarter valued at $244,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Vericel by 7.1% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 27,960 shares of the biotechnology company’s stock valued at $1,454,000 after buying an additional 1,845 shares in the last quarter. Texas Permanent School Fund Corp raised its stake in shares of Vericel by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 41,768 shares of the biotechnology company’s stock valued at $2,173,000 after buying an additional 541 shares in the last quarter. Swiss National Bank raised its stake in shares of Vericel by 0.4% in the 1st quarter. Swiss National Bank now owns 89,500 shares of the biotechnology company’s stock valued at $4,656,000 after buying an additional 400 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Vericel in the 1st quarter valued at $990,000.

Insider Buying and Selling at Vericel

In other Vericel news, CEO Dominick Colangelo sold 17,500 shares of the stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total value of $724,150.00. Following the completion of the sale, the chief executive officer now directly owns 220,937 shares of the company’s stock, valued at $9,142,373.06. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Vericel news, CEO Dominick Colangelo sold 17,500 shares of the stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total value of $724,150.00. Following the completion of the sale, the chief executive officer now directly owns 220,937 shares of the company’s stock, valued at $9,142,373.06. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Steven C. Gilman sold 5,833 shares of the stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $41.36, for a total transaction of $241,252.88. Following the completion of the sale, the director now directly owns 11,000 shares of the company’s stock, valued at approximately $454,960. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 29,166 shares of company stock valued at $1,200,764 in the last ninety days. Company insiders own 5.20% of the company’s stock.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.